Journal of Clinical Investigation · 2019 · 58 citations · 49 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmunotherapy For Solid TumorsOncogenic VirusesOncolytic Virus ImmunotherapyOncolytic Virus TherapyImmune Cell ActivationImmune Checkpoint Inhibitor TherapyIntratumoral AdministrationOncolytic Viral TherapyResistance To Checkpoint InhibitorsSmall Cell Lung Cancer ImmunotherapySmall Cell Lung Cancer TreatmentTumor Immune Cell Infiltration
Oncolytic virotherapy has been proposed as an ablative and immunostimulatory treatment strategy for solid tumors that are resistant to immunotherapy alone; however, there is a need to optimize host immune activation using preclinical immunocompetent models in previously untested common adult tumors. We studied a modified oncolytic myxoma virus (MYXV) that shows high efficiency for tumor-specific cytotoxicity in small-cell lung cancer (SCLC), a neuroendocrine carcinoma with high mortality and modest response rates to immune checkpoint inhibitors. Using an immunocompetent SCLC mouse model, we demonstrated the safety of intrapulmonary MYXV delivery with efficient tumor-specific viral replication and cytotoxicity associated with induction of immune cell infiltration. We observed increased SCLC survival following intrapulmonary MYXV that was enhanced by combined low-dose cisplatin. We also tested intratumoral MYXV delivery and observed immune cell infiltration associated with tumor necrosis and growth inhibition in syngeneic murine allograft tumors. Freshly collected primary human SCLC tumor cells were permissive to MYXV and intratumoral delivery into patient-derived xenografts resulted in extensive tumor necrosis. We confirmed MYXV cytotoxicity in classic and variant SCLC subtypes as well as cisplatin-resistant cells. Data from 26 SCLC human patients showed negligible immune cell infiltration, supporting testing MYXV as an ablative and immune-enhancing therapy.
49
Effects of an Rb mutation in the mouse
Tyler Jacks, Amin Fazeli, Earlene M. Schmitt et al. · Nature · 1992 · 1.8K citations
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas, Reinhard Dummer, Igor Puzanov et al. · Cell · 2017 · 1.5K citations · Full text
Medicine, Immunology, Oncology +12
Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +14